Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma

Luciano Quaranta, Andreas Katsanos, Irene Floriani, Ivano Riva, Andrea Russo, Anastasios G P Konstas

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5% solution administered twice daily versus timolol 0.1% in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5% solution or timolol 0.1% hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after timolol 0.1% hydrogel (P

Original languageEnglish
Pages (from-to)1552-1557
Number of pages6
JournalJournal of Clinical Pharmacology
Volume52
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Timolol
Intraocular Pressure
Blood Pressure
Ambulatory Blood Pressure Monitoring
Hydrogel
Manometry
Sample Size
Cross-Over Studies
Primary Open Angle Glaucoma
Gels
Research Personnel

Keywords

  • glaucoma
  • primary open-angle glaucoma
  • Timogel
  • Timolol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. / Quaranta, Luciano; Katsanos, Andreas; Floriani, Irene; Riva, Ivano; Russo, Andrea; Konstas, Anastasios G P.

In: Journal of Clinical Pharmacology, Vol. 52, No. 10, 10.2012, p. 1552-1557.

Research output: Contribution to journalArticle

Quaranta, Luciano ; Katsanos, Andreas ; Floriani, Irene ; Riva, Ivano ; Russo, Andrea ; Konstas, Anastasios G P. / Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. In: Journal of Clinical Pharmacology. 2012 ; Vol. 52, No. 10. pp. 1552-1557.
@article{4c1ec9763b7f4c80aa956eb2aa8f749a,
title = "Circadian intraocular pressure and blood pressure reduction with timolol 0.5{\%} solution and timogel 0.1{\%} in patients with primary open-angle glaucoma",
abstract = "Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5{\%} solution administered twice daily versus timolol 0.1{\%} in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5{\%} solution or timolol 0.1{\%} hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5{\%} and 18.9 ± 0.8 mm Hg after timolol 0.1{\%} hydrogel (P",
keywords = "glaucoma, primary open-angle glaucoma, Timogel, Timolol",
author = "Luciano Quaranta and Andreas Katsanos and Irene Floriani and Ivano Riva and Andrea Russo and Konstas, {Anastasios G P}",
year = "2012",
month = "10",
doi = "10.1177/0091270011420254",
language = "English",
volume = "52",
pages = "1552--1557",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma

AU - Quaranta, Luciano

AU - Katsanos, Andreas

AU - Floriani, Irene

AU - Riva, Ivano

AU - Russo, Andrea

AU - Konstas, Anastasios G P

PY - 2012/10

Y1 - 2012/10

N2 - Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5% solution administered twice daily versus timolol 0.1% in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5% solution or timolol 0.1% hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after timolol 0.1% hydrogel (P

AB - Purpose: To investigate the circadian and blood pressure (BP) reduction obtained with timolol maleate 0.5% solution administered twice daily versus timolol 0.1% in gel-forming carbomer administered in the morning in patients with primary open-angle glaucoma (POAG). Methods: This investigator-masked, crossover study prospectively enrolled naive POAG patients not receiving systemic cardiovascular medications. Following a baseline evaluation, they were randomized to receive a timolol 0.5% solution or timolol 0.1% hydrogel for 2 months and then switched to the alternative medication for a further 2 months. Intraocular pressure (IOP) phasing (sitting Goldmann tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine Perkins tonometry at 2 am and 6 am) and ambulatory home BP monitoring were measured at baseline and after each treatment period. Results: On the basis of a prospective sample size estimate, 28 patients were analyzed. Mean 24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after timolol 0.1% hydrogel (P

KW - glaucoma

KW - primary open-angle glaucoma

KW - Timogel

KW - Timolol

UR - http://www.scopus.com/inward/record.url?scp=84870462150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870462150&partnerID=8YFLogxK

U2 - 10.1177/0091270011420254

DO - 10.1177/0091270011420254

M3 - Article

C2 - 22110164

AN - SCOPUS:84870462150

VL - 52

SP - 1552

EP - 1557

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 10

ER -